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SUPPLEMENTARY NOTES
ABSTRACT
During the peri od October 22, 2009 to Oc tober 21, 2010, the proj ect personnel conti nued to perform chemi cal/physical analyses on bul k pharmaceuti cal substances and formul ated dr ug products, and to manufacture dosage formul ations of interest to the USAMRMC Drug Devel opment Program for parasi tic and infectious diseases, chemical and biological defense, etc. Speci fic obj ectives were to desi gn, devel op, val idate, and appl y methods to deter mine chemi cal and physi cal characteristics of t he bulk drugs, drug products, to det ermine their stability under defined conditions, and to coordinate and work with subcontractors to produce an intravenous dosage form of artesunate. The overall objective of this project is the operation of an analytical laboratory to determine the identity, purity, strength, quality, physical and chemical properties, and stability of bulk pharmaceutical substances and formulated drug products, and to develop and manufacture, in limited quantities, dosage formulations of interest of the USAMRMC Drug Development Program for parasitic and infectious diseases, chemical and biological defense, anti-viral studies, etc. Specific objectives are to design, develop, validate, and execute methods to determine the following characteristics of candidate bulk pharmaceutical substances and formulated drugs, and to develop and manufacture, in limited quantities, dosage formulations.
• Identity, purity, and strength; Dalton Pharma Services is to fill 9,000 vials of sterile AS under cGMP aseptic condition, test and release the drug product, and to conduct stability studies under cGMP shelf-life and accelerated conditions. Afton Scientific Corporation is to produce, under cGMP conditions, 10,500 vials of sterile phosphate dissolution medium, which is the second component of the artesunic acid IV drug product. Afton also served in this capacity in 2004 for the first batch of artesunic acid IV drug product, SRI batch # 14462-16.
A second emphasis of our project work is to maintain the acceptability of the first batch of artesunic acid IV drug product by continuing stability studies at -20°C and +5°C. Drug product units stored at these temperatures for 51 months and 48 months respectively, after they had been stored at ~20 months at 18-20°C, continue to pass the chemical, and sterility/endotoxin requirements. We continue to improve our sample preparation of the crucial chemical test, <USP 788> particulate for injection. The improvement was centered on minimizing agitation of the AS/phosphate mixture and on lengthening the air bubble dissipation time, prior to counting the particulates in the constituted solution.
The third emphasis is our core effort, which is to perform identity and assay on bulk drugs and drug products of interest to the Army.
SUMMARY/CONCLUSIONS
Subcontractor Steris Isomedix Services successfully sterilized the artesunic acid active pharmaceutical ingredient.
Subcontractor Dalton Pharma Services successfully completed its manufacture and release of 9,000 vials of artesunate IV dosage form in March 2010.
Afton Scientific Corporation successfully completed its manufacture and release of 10,500 vials of the phosphate dissolution medium in February 2010.
Stability studies on both components commenced at Dalton in March 2010.
Results from continuing stability studies on the first batch of artesunate IV dosage form, SRI batch# 14462-16, stored at 5°C have shown stability for at least 48 months and enabled its clinical use to continue. Analogously, its storage at -21°C has shown stability for 51 months, also enabling its clinical use to continue.
The project team continues to provide solutions to the Army's analytical chemical problems.
